GHK-Cu’s story starts in blood

Before the skin cream, there was liver tissue

Loren Pickart isolated GHK from human plasma in 1973 as a factor that prompted aged liver tissue to synthesize proteins more like younger tissue. The 2015 review recounts that origin, along with an age-associated fall in plasma GHK from about 200 ng/mL at age 20 to about 80 ng/mL by age 60. Neither observation proves that replacing it reverses aging.

I expected the history to begin with a wrinkle. Liver tissue is a more peculiar beginning, and it makes the later cosmetic reputation feel narrower than the original question. It also makes the temptation to tell a rejuvenation story understandable. The rejuvenation story remains unproven.

The 1988 collagen experiment put GHK-Cu into cultures of human fibroblasts, the cells that make much of skin’s supporting material. Collagen synthesis began to rise between 10^-12 and 10^-11 M and peaked near 10^-9 M. The cell count did not change: the existing cells were doing more collagen-making work. These concentrations describe a culture-dish experiment; amounts for a person remain unestablished.

That distinction gives the old experiment much of its appeal. A visible increase can come from more cells or different behaviour in the cells already present; here, the authors separated the two.

Wound studies found more new blood vessels

Another part of the history begins inside a larger protein. Laboratory work with endothelial cells and an in vivo angiogenesis assay found that breaking down SPARC released copper-binding fragments, including GHK and KGHK, that stimulated angiogenesis. That is the formation of new blood vessels. The experiment found sequence-specific activity and did not require prior copper binding for that angiogenic effect.

This is where a tidy story about copper becomes untidy. The fibroblast-culture MMP-2 experiment required the copper-bound form; the SPARC-fragment angiogenesis work did not require prior copper binding. Different experiments are asking about different actions. The distinction spoils the tidy explanation I expected.

In GHK-modified alginate gels, human stem/stromal cells in culture released more VEGF, a signal involved in blood-vessel growth. The work examined cells and a material designed for tissue engineering; patient outcomes were outside its scope. Later GHK peptide nanofibers embedded in a hyaluronic-acid gel were tested in human cells and mouse wounds. The wound page follows those materials further.

Evidence boundary / Clinical access

Prescription access and preclinical findings

At mypromise.com, injectable GHK-Cu is now among the products prescribed by Promise Peptides; a licensed U.S. clinician assesses each request before deciding whether to issue the needed prescription. Some requests are declined; only patients in the U.S. can receive care, and their state and treatment set further limits. That compounded medication has no FDA approval, and prescription access is not evidence that blood-vessel growth in lab gels or cells predicts a human outcome. The distinction matters here because the mechanistic record above remains preclinical regardless of how a prescription is obtained.

The gene number is bigger than the clinical answer

The 2018 gene-data review reports that GHK modulated approximately 31.2% of human genes at a 50%-or-greater expression-change threshold. Of the affected genes, 59% increased expression and 41% decreased it. The frequently quoted ~4,000 figure is an extrapolation; the threshold table reports on the order of 2,100 genes.

Expression describes how actively a gene is being used. The count concerns gene activity rather than repaired organs. The same analysis describes 41 genes increasing and 1 decreasing in the ubiquitin-proteasome system, which helps cells dispose of proteins. That is an intriguing direction for further work, but a database signature still needs validation at the protein level and in living organisms.

I trust the specific collagen experiment more than the size of a gene list. That is a judgment about the question each result answers, not a dismissal of the gene work. A huge signature can suggest experiments without settling the outcome of any of them.

The blood clock is still missing

The rat plasma study tracked free GHK breaking down into histidyl-lysine after intravenous administration. It did not establish the half-life of injected GHK-Cu in humans. No validated human pharmacokinetic data establish how systemic GHK-Cu is absorbed, distributed or cleared.

Similarly, less anxious behaviour in rats given GHK and its analogs is a rodent finding about the free peptide; a human brain benefit from GHK-Cu remains undemonstrated. The distinctions in these names and species are doing real work.

Much of the foundational work and the broad reviews comes from Pickart and colleagues, as the reading list makes apparent. Replication by other groups remains limited for the broad gene and anti-aging claims. I’d welcome a less expansive headline backed by a direct, repeatable human outcome.